Whitehawk Therapeutics Divests Aadi Subsidiary to Kaken Pharmaceuticals
March 26, 2025
Whitehawk Therapeutics completed the divestiture of Aadi Subsidiary, Inc. (including the Aadi Bioscience name, trademarks, and the FYARRO (sirolimus protein-bound particles for injectable suspension) business) to Kaken Pharmaceuticals for $100 million in cash plus customary adjustments. Whitehawk plans to use proceeds (along with a $100M PIPE financing) to develop its ADC portfolio and for general corporate and working capital needs.
- Buyers
- Kaken Pharmaceuticals, KAKEN INVESTMENTS INC.
- Targets
- Aadi Subsidiary, Inc.
- Sellers
- Aadi Bioscience, Inc., Whitehawk Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Transaction Type
- Divestiture
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.